Analytical Data
-
Gene name
SNCA
-
简介
SNCA proteins are critical for synaptic activity and regulate vesicle trafficking and neurotransmitter release. As a monomer, it enhances the vesicle exocytosis process. SNCA Protein, Mouse is the recombinant mouse-derived SNCA protein, expressed by E. coli , with tag free.
- Application
-
Alternative Names
Alpha-synuclein; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP; Snca
-
Species
Mouse
-
Source
E. coli
-
Tag
Tag Free
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
O55042-1
-
Expression Region
M1-A140
-
Protein Length
Full Length of Isoform-1
-
Molecular Weight
17.0 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of SNCA (Alpha-synuclein) recombinant proteins has gained significant attention due to their pivotal role in neurodegenerative diseases, particularly Parkinson's disease. Alpha-synuclein is a neuronal protein that is predominantly found in the brain, where it is involved in synaptic function and neurotransmitter release. Misfolding and aggregation of SNCA into insoluble fibrils are hallmark features of Parkinson’s disease and certain other synucleinopathies, leading to the formation of Lewy bodies, which are toxic to neurons. Understanding the structure and dynamics of SNCA at the molecular level is crucial for elucidating the mechanisms underlying its pathogenesis. Researchers utilize recombinant techniques to produce SNCA protein in a controlled environment, enabling detailed studies of its biochemical properties and aggregation behavior. These investigations are essential for developing therapeutic strategies aimed at mitigating SNCA-related toxicities, such as small molecules that can prevent aggregation or enhance the natural clearance of misfolded proteins. Additionally, recombinant SNCA is instrumental in the development of animal models and in vitro systems that replicate the disease state, facilitating drug discovery and the exploration of potential interventions. Overall, the study of SNCA recombinant proteins provides critical insights into the molecular pathways of neurodegeneration and holds promise for novel therapeutic approaches in targeting synucleinopathies.
